Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways (Q38071004)

28 August 2017

1 reference

title

Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways (English)

1 reference

28 August 2017

0 references

3

1 reference

28 August 2017

Tiago Silva

1

0 references

José Teixeira

object named as

José Teixeira

series ordinal

2

0 references

Fernanda Borges

object named as

Fernanda Borges

series ordinal

4

0 references

language of work or name

English

0 references

publication date

20 December 2012

1 reference

Angewandte Chemie International Edition

28 August 2017

0 references

volume

52

1 reference

28 August 2017

1110-1121

1 reference

28 August 2017

4

1 reference

The lipid and non-lipid effects of statins

28 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins: mechanism of action and effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Cognitive impairment: dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

The world of dementia beyond 2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

A new clinical scale for the staging of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

A century of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Alpha-helix structure in Alzheimer's disease aggregates of tau-protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Biochemical markers and risk factors of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Revisiting the cholinergic hypothesis in the development of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Oxidative stress hypothesis in Alzheimer's disease: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Oxidative stress in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Therapeutics for Alzheimer's disease based on the metal hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Copper in the brain and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Role of metal dyshomeostasis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Inflammation in the early stages of neurodegenerative pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Structural basis for increased toxicity of pathological aβ42:aβ40 ratios in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Oxidative stress in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Toward a unifying hypothesis in the development of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

The essential role of lipids in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Isoprenoids and Alzheimer's disease: a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statin use and the risk of Alzheimer's disease: the MIRAGE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Reduced risk of incident AD with elective statin use in a clinical trial cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Endolysosome mechanisms associated with Alzheimer's disease-like pathology in rabbits ingesting cholesterol-enriched diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

The 32-year relationship between cholesterol and dementia from midlife to late life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Alzheimer's disease: the cholesterol connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Cholesterol and statins in Alzheimer's disease: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Therapeutic potential of statins in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Facts, myths, and controversies in vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins and their influence on brain cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Mechanisms of disease: new therapeutic strategies for Alzheimer's disease--targeting APP processing in lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Chemical biology of protein isoprenylation/methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Isoprenoids, small GTPases and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Oxysterols and neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Role of cholesterol and lipid organization in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins--a cure-all for the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Association between apolipoprotein E gene polymorphism and the risk of vascular dementia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Drug Insight: using statins to treat neuroinflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins in the treatment of central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins--treatment option for central nervous system autoimmune disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins: mechanisms of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins: multiple neuroprotective mechanisms in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statins as anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Effects of pitavastatin on cerebral blood flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Atorvastatin and Aβ(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Alzheimer’s Disease: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

Statin Use and the Risk of Incident Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204964

21 January 2018

Identifiers

DOI

10.1002/ANIE.201204964

1 reference

28 August 2017

1 reference

PubMed ID

23280829